Breaks Categories: Analyst Alerts

WednesdayJun 21, 2017 12:30 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Axsome Therapeutics, Inc. (NASDAQ: AXSM)

Following Axsome Therapeutics, Inc.’s (NASDAQ: AXSM) appointment of Myrtle Potter to its board of directors, Aegis Capital reiterated its ‘Buy’ rating and price target of $20 on shares of the company’s stock. Calling the appointment “incrementally positive,” the analyst voiced confidence that the appointment of the former Genentech executive, specifically her experience in the commercialization process, adds value to Axsome’s board. For more information, visit www.axsome.com About Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome’s product candidate…

Continue Reading

ThursdayJun 15, 2017 12:16 pm

NetworkNewsBreaks – Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Reiterated with “Buy” Rating at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $25 on shares of Concert Pharmaceuticals, Inc.’s (NASDAQ: CNCE) stock following news that the company has entered into a $30 million venture debt financing agreement with Hercules Capital, Inc. The analyst noted that the deal helps extend the company’s cash runway by bringing Concert’s cash on hand to approximately $114 million, which should fund operations through the end of 2018. Additionally, the analyst noted the company’s upcoming catalysts, including the close of its CTP-656 deal in the fourth quarter of 2017; a CTP-543 phase 2a trial in Alopecia Areata expected in…

Continue Reading

MondayJun 12, 2017 12:20 pm

NetworkNewsBreaks – SeeThruEquity Updates Coverage on BioSig Technologies, Inc. (BSGM)

SeeThruEquity has issued a company update and price target of $3.53 on shares of BioSig Technologies, Inc. (OTCQB: BSGM). Among other highlights, the SeeThruEquity analyst noted the recent expansion of BioSig’s collaboration agreement with the Mayo Clinic. The expanded technology and clinical development partnership has a 10-year term and includes cash warrants and licensing opportunities as well as joint intellectual property filings. The analyst also noted upcoming catalysts for the company, including BioSig’s plans to submit a 510(k) application for clearance to commercialize the PURE EP™ by the third quarter of 2017, and news that the company aims to up-list…

Continue Reading

MondayJun 12, 2017 9:21 am

NetworkNewsBreaks – Nektar Therapeutics (NASDAQ: NKTR) Receives “Buy” Rating at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $27 on Nektar Therapeutics (NASDAQ: NKTR), stating that the company’s NKTR-214 has wide applicability and the ability to be combined effectively with multiple modalities such as checkpoint inhibitors, cell therapies, small molecules, or vaccines. The company has many upcoming catalysts, including an expansion of the Bristol-Myers Squibb Opdivo collaboration expected in the third quarter of 2017 and a collaboration with Roche Holding's Tecentriq trial that is expected to initiate by mid-2017. For more information, visit www.nektar.com About Nektar Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops…

Continue Reading

MondayJun 12, 2017 9:19 am

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Ocera Therapeutics, Inc. (NASDAQ: OCRX)

Following Ocera Therapeutics, Inc.’s (NASDAQ: OCRX) Key Opinion Leader (KOL) conference call on hepatic encephalopathy and other complications of liver disease, Aegis Capital reiterated its ‘Buy’ rating and price target of $3 on shares of the company’s stock. The analyst noted the importance of OCR-002’s potential to reduce hospital stays by 1.5 days and believes that, combined with the IV formulation, the prospective savings for the hospitals could encourage them to adopt OCR-002 when available. Additionally, the company also recently initiated the dosing phase of its phase 1/2a trial of oral OCR-002 in cirrhosis. The end of phase 2 meeting…

Continue Reading

MondayJun 12, 2017 9:17 am

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Aegis Capital has reiterated a ‘Buy’ rating and issued a price target of $25 on shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) stock. The news follows the company’s recent report of two patent wins in the EU. The Opposition Division (OD) of the European Patent Office has revoked another FibroGen, Inc. hypoxia-inducible factor (HIF) related patent in Europe. Additionally, Akebia’s challenge to a second HIF-related patent resulted in FibroGen considerably narrowing the claims to only cover an indication for vadadustat that Akebia does not intend to develop. The analyst noted its belief that the company now holds a strong IP position…

Continue Reading

FridayJun 09, 2017 12:22 pm

NetworkNewsBreaks – Novocure (NASDAQ: NVCR) Reiterated with “Buy” Rating at Aegis Capital

Aegis Capital has reiterated a ‘Buy’ rating and price target of $14 on shares of Novocure’s (NASDAQ: NVCR) stock following the company’s news that Health Care Service Corporation (HCSC) will cover Optune for members who have newly diagnosed glioblastoma (GBM). The analyst said the additional coverage for Optune should result in a higher percentage of accrual-based revenue over time. The positive decision from HCSC brings the count of covered Americans to 204 million and is effective as of June 15, 2017. For more information, visit www.novocure.com About Novocure Novocure is an oncology company developing a profoundly different cancer treatment utilizing…

Continue Reading

FridayJun 09, 2017 12:20 pm

NetworkNewsBreaks – Aegis Capital Reiterates “Buy” Rating on Revance Therapeutics, Inc. (NASDAQ: RVNC)

Following Revance Therapeutics, Inc.’s (NASDAQ: RVNC) report of positive results from its phase 2 clinical study of RT002 to treat moderate-to-severe isolated cervical dystonia (CD), Aegis Capital reiterated its ‘Buy’ rating and price target of $36 on shares of the company’s stock. Additionally, Revance is in the process of enrolling for its pivotal, phase 3 Sakura trials. The identical trials taking place in the U.S. and Canada will randomize subjects 2:1 to receive either RT002 or placebo. The analyst noted that based off of the results seen in the phase 2 CD trial, they believe it is likely that the…

Continue Reading

TuesdayJun 06, 2017 12:44 pm

NetworkNewsBreaks – CTI BioPharma Corp. (NASDAQ: CTIC) Prices $45M Offering of Convertible Preferred Stock; Shares Down, but Lift from New 52-Week Low

CTI BioPharma Corp. ("CTI") (NASDAQ: CTIC) this morning priced its underwritten public offering of 22,500 shares of its Series N-3 Preferred Stock at $2,000 per share. The company said it expects gross proceeds from the offering of $45 million. Net proceeds will be used to conduct the PAC203 clinical trial; submit a new Marketing Authorization Application for pacritinib to the European Medicines Agency; conduct additional research concerning the possible application of pacritinib in indications outside of myelofibrosis; and complete the PIX306 clinical trial, as well as for general corporate purposes, which may include funding research and development, conducting preclinical and clinical…

Continue Reading

MondayJun 05, 2017 12:21 pm

NetworkNewsBreaks – Celsion Corp. (NASDAQ: CLSN) Presents “Encouraging” OVATION Study Results; Shares Surge on Heavy Volume

Shares of Celsion (NASDAQ: CLSN) are up 57.8% on volume of 15.98 million in mid-day trade after the oncology drug development company issued an update on its OVATION study, a phase Ib dose escalating clinical trial assessing the combination of GEN-1, Celsion’s DNA-based immunotherapy, with the standard of care for the treatment of newly diagnosed patients with advanced ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. “The OVATION study has accrued patients from four major research cancer centers.  We have seen highly promising clinical findings including a patient with a complete pathological response along with a very high…

Continue Reading